If you have Medicare and your doctor has been telling you about a new daily pill for weight loss, this post is for you. Foundayo is real, it’s FDA-approved, and starting July 1, 2026, it’s covered for $50 a month under Medicare’s GLP-1 Bridge program for eligible beneficiaries.
This is genuinely new. Foundayo got FDA approval on April 1, 2026, which makes it one of the youngest drugs ever to be added to a major Medicare program. CMS updated the Bridge to include it on April 6, five days after approval. That kind of speed is unusual.
I’m not on Foundayo myself. I’ve been on Zepbound through my employer’s insurance for a while. But I’ve been writing about the Bridge program because the rules are confusing, the news coverage is uneven, and a lot of people are about to get tripped up at the pharmacy counter on July 1 because their prescription doesn’t match what’s actually covered. Foundayo is one of the things people are most likely to get wrong.
What Foundayo Is
Foundayo is the brand name for orforglipron, an oral GLP-1 medication made by Eli Lilly. It’s a once-daily pill, taken with or without food. That last part matters more than it sounds.
The other oral GLP-1 on the market for obesity is the pill version of Wegovy (oral semaglutide). Both are pills. They’re not interchangeable, though. Oral Wegovy has to be taken first thing in the morning, on a completely empty stomach, with no more than four ounces of water, and you can’t eat or drink anything else for at least 30 minutes. That’s a real daily logistics burden, especially for someone managing other morning medications.
Foundayo doesn’t have any of those restrictions. Take it whenever, with food or without, with whatever you’re drinking. For someone who’s been resistant to GLP-1s because they don’t want to inject, and who has tried oral Wegovy and found the timing too punishing, Foundayo is a meaningful third option.
How Effective Is It?
This is where Foundayo’s tradeoff shows up. In the ATTAIN-1 phase 3 trial, patients on the highest dose lost about 12% of their body weight at 72 weeks. The Wegovy oral pill landed around 17% in trials. Injectable Wegovy and Zepbound have hit 15% and 22% respectively in their pivotal trials.
So Foundayo is real, but it’s the least potent of the obesity GLP-1s available right now. That’s not a knock on the drug. It’s a tradeoff for convenience. If you’re someone for whom a weekly injection is a non-starter and the morning timing window of oral Wegovy doesn’t fit your life, 12% weight loss is still well into clinically meaningful territory. The American Heart Association considers anything over 5% weight loss in someone with obesity to be a meaningful intervention for cardiovascular risk. 12% is more than double that.
For Medicare-age beneficiaries specifically, the convenience angle matters more than the headline number. Injections require some hand strength, vision to read the dose, and the ability to maneuver a pen. None of that is a problem for most people, but it’s a problem for some. A pill solves all of it.
Foundayo Coverage Under the Medicare GLP-1 Bridge
The Medicare GLP-1 Bridge covers Foundayo at a $50 monthly copay starting July 1, 2026, running through December 31, 2027. All formulations of Foundayo are covered, which is simpler than the Zepbound situation (where only the KwikPen formulation qualifies, not the cheaper LillyDirect vials).
To qualify for Foundayo coverage under the Bridge, you need to meet the same eligibility criteria as for Wegovy or Zepbound:
- BMI 35 or higher, or
- BMI 30 or higher with HFpEF, uncontrolled hypertension despite two medications, or chronic kidney disease stage 3a or above, or
- BMI 27 or higher with prediabetes, prior heart attack, prior stroke, or symptomatic peripheral artery disease
You also need to be enrolled in a Medicare Part D plan or a Medicare Advantage plan with drug coverage. Original Medicare alone (Parts A and B) won’t cut it. And the prescription has to be paired with a documented nutrition and physical activity plan from your provider, which is the lifestyle modification piece required by the FDA label.
I’ve written up the full eligibility breakdown, prior authorization checklist, and the gotchas everyone’s missing in the main Bridge guide. Worth reading if you haven’t yet. The prior auth rules are stricter than most news coverage suggests.
Should You Ask Your Doctor About Foundayo?
Some honest framing on this. I’m not going to tell you Foundayo is the right drug for you. That’s between you and your doctor. But here are the conversations worth having if you’re on Medicare and trying to decide:
If you’re already on Wegovy or Zepbound and it’s working, don’t switch just because Foundayo is new. The injectables produce more weight loss. There’s no good reason to step down to a less potent option if the current one is fine.
If you’ve been resistant to starting GLP-1s because of injections, Foundayo opens a real door. It’s worth a serious conversation with your prescriber about whether 12% weight loss meets your goals.
If you’re already on oral Wegovy and the timing window is killing you, ask about switching to Foundayo. Same drug class, same coverage, no morning fast.
If you’ve never been on a GLP-1 and you have a reasonable BMI in the 27 to 32 range, you might find the lower potency of Foundayo is plenty for what you need. Starting milder and seeing how you respond is a defensible approach.
What to Do Before July 1
The same prep work applies to Foundayo as to the other Bridge drugs. Get a clinic visit on the books for May or June. Make sure your BMI is documented from an actual measurement, not self-reported. Make sure the qualifying diagnosis (if you’re on the BMI 27+ or 30+ pathway) is in the chart with the right ICD-10 code. Make sure your provider documents the nutrition and physical activity plan.
Then, when July 1 hits, your prescriber submits the prior authorization to the CMS central processor (not your Part D plan), and if everything’s in order, you walk into the pharmacy and pay $50.
The patients who’ll have problems are the ones whose paperwork wasn’t ready. That’s avoidable. The patients who’ll get the prescription denied because Foundayo “isn’t on their plan’s formulary” are dealing with a Part D plan that’s confused about the Bridge being separate from regular Part D coverage. That’s also avoidable, but it’ll take a phone call and possibly an appeal. Worth knowing in advance so you don’t panic when it happens.
The Bottom Line
Foundayo is the newest GLP-1 obesity drug on the market, the only one that can be taken any time of day with or without food, and it’s covered under the Medicare GLP-1 Bridge starting July 1. It’s less potent than the injectables but a real option for people who want a pill. Eligibility and documentation rules are the same as for Wegovy and Zepbound under the Bridge.
If any of this applies to you or a parent on Medicare, the action item is simple: get the documentation in the chart this month so the prior authorization goes through cleanly in early July.
Source: CMS Medicare GLP-1 Bridge official page (last updated April 6, 2026 to include Foundayo).